The use of the combination of P + CHT can therefore be considered in the case of effort for a higher chance of reducing the tumor mass (e.g. bulky symptomatic tumor), however, this treatment does not probably lead to a better prognosis for patients compared to P alone. The gene discussed is SLC5A7; the disease is neoplasm.